IX．甲状腺がんにおける抗がん薬治療

• 資料種別: 記事
• タイトル: IX．甲状腺がんにおける抗がん薬治療
• 著者標目: 山﨑 知子
• 出版年月日等: 2024-04-10
• 出版年（W3CDTF）: 2024-04-10
• タイトル（掲載誌）: 日内会誌
• 巻号年月日等（掲載誌）: 113 4
• 掲載巻: 113
• 掲載号: 4
• 掲載ページ: 668-675
• 掲載年月日（W3CDTF）: 2024-04-10
• ISSN（掲載誌）: 00215384
• 出版事項（掲載誌）: The Japanese Society of Internal Medicine
• 本文の言語コード: ja
• 件名標目: 甲状腺がん; 抗がん薬治療; マルチキナーゼ阻害薬; コンパニオン診断; 遺伝子パネル検査
• 対象利用者: 一般
• DOI: 10.2169/naika.113.668; https://doi.org/10.2169/naika.113.668
• 関連情報（URI）: https://www.jstage.jst.go.jp/article/naika/113/4/113_668/_pdf
• 参照: State-of-the-Art Strategies for Targeting <i>RET</i>-Dependent Cancers; https://cir.nii.ac.jp/crid/1360013170911469824; Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial; https://cir.nii.ac.jp/crid/1360016867496783104; Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma; https://cir.nii.ac.jp/crid/1360016978856019200; Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study; https://cir.nii.ac.jp/crid/1360017279857931392; Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial; https://cir.nii.ac.jp/crid/1360021395151967744; Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study; https://cir.nii.ac.jp/crid/1360021397006324608; Pralsetinib in patients (pts) with advanced or metastatic <i>RET</i>-altered thyroid cancer (TC): Updated data from the ARROW trial.; https://cir.nii.ac.jp/crid/1360023719137758848; Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer; https://cir.nii.ac.jp/crid/1360023719872210688; KIF5B-RET fusions in lung adenocarcinoma; https://cir.nii.ac.jp/crid/1360283691784925696; Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers; https://cir.nii.ac.jp/crid/1360292621227758080; Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis; https://cir.nii.ac.jp/crid/1360294646477396736; Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers; https://cir.nii.ac.jp/crid/1360294751349566464; The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020; https://cir.nii.ac.jp/crid/1360298762021024896; Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial; https://cir.nii.ac.jp/crid/1360579819984124416; Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study; https://cir.nii.ac.jp/crid/1360579928932127616; Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial; https://cir.nii.ac.jp/crid/1360584346960945152; 1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial; https://cir.nii.ac.jp/crid/1360586669086407552; The landscape of kinase fusions in cancer; https://cir.nii.ac.jp/crid/1360855567863008896; TRK inhibitors in TRK fusion-positive cancers; https://cir.nii.ac.jp/crid/1360855568861327360; Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?; https://cir.nii.ac.jp/crid/1360855571556432512; Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing; https://cir.nii.ac.jp/crid/1360861292491992704; A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).; https://cir.nii.ac.jp/crid/1360868143805154560; Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial; https://cir.nii.ac.jp/crid/1361137044497230848; Long-Term Outcome of 444 Patients with Distant Metastases from Papillary and Follicular Thyroid Carcinoma: Benefits and Limits of Radioiodine Therapy; https://cir.nii.ac.jp/crid/1361418519560836992; BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance; https://cir.nii.ac.jp/crid/1361699994391517824; Molecular genetics and diagnosis of thyroid cancer; https://cir.nii.ac.jp/crid/1361981469446764928; Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer; https://cir.nii.ac.jp/crid/1361981470685926272; Prognostic Factors and Treatment Outcomes for Anaplastic Thyroid Carcinoma: ATC Research Consortium of Japan Cohort Study of 677 Patients; https://cir.nii.ac.jp/crid/1362262944299892992; PD-1 Blockade in Anaplastic Thyroid Carcinoma; https://cir.nii.ac.jp/crid/1362544419650806400; Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial; https://cir.nii.ac.jp/crid/1362544420729692416; NTRK fusion-positive cancers and TRK inhibitor therapy; https://cir.nii.ac.jp/crid/1362825894326542208; Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma; https://cir.nii.ac.jp/crid/1362825894489398656; Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer; https://cir.nii.ac.jp/crid/1363107370994808960; Chemotherapy of Thyroid Cancer with Adriamycin; https://cir.nii.ac.jp/crid/1363388844419972096; Genomic Characterization of Differentiated Thyroid Carcinoma; https://cir.nii.ac.jp/crid/1363670318510290688; Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study; https://cir.nii.ac.jp/crid/1363951794975688448; Landscape of Microsatellite Instability Across 39 Cancer Types; https://cir.nii.ac.jp/crid/1363951795541234560; A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma; https://cir.nii.ac.jp/crid/1363951795658228608; Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas; https://cir.nii.ac.jp/crid/1364233269919272192
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org

• 要約等: <p>甲状腺がんの薬物療法は，マルチキナーゼ阻害薬であるレンバチニブ，ソラフェニブ，バンデタニブ，およびRET阻害薬，NTRK阻害薬，BRAF阻害薬，免疫チェックポイント阻害薬などの臓器横断的な薬剤の承認で急激に進歩した．甲状腺がんでは治療につながりやすいActionableな遺伝子変異が多いとされ...